Pfizer Inc. $PFE Shares Bought by Sigma Planning Corp

Sigma Planning Corp raised its holdings in Pfizer Inc. (NYSE:PFE) by 22.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 210,735 shares of the biopharmaceutical company’s stock after buying an additional 39,162 shares during the quarter. Sigma Planning Corp’s holdings in Pfizer were worth $5,074,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new position in Pfizer during the 2nd quarter valued at approximately $26,000. Field & Main Bank purchased a new position in shares of Pfizer in the second quarter worth $27,000. HFM Investment Advisors LLC raised its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. lifted its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $27.95 on Monday. The firm’s fifty day moving average is $25.55 and its two-hundred day moving average is $26.30. The firm has a market cap of $159.31 billion, a price-to-earnings ratio of 36.78 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Analyst Ratings Changes

Several research firms recently issued reports on PFE. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and cut their price objective for the company from $32.00 to $28.00 in a report on Monday, July 6th. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.